Cystic fibrosis treatment could improve lung function
A new treatment for cystic fibrosis (CF) could improve lung function in patients, results suggest.
ETD001, developed by biopharmaceutical company Enterprise Therapeutics, was trialled in a Phase II study as an inhaled treatment in the 10% of people with CF with the highest unmet medical need, who do not benefit from treatment with CFTR modulators.
The treatment, an investigational inhaled epithelial sodium channel (ENaC) blocker, is designed to increase lung function by improving mucus clearance and reducing airway obstruction.
Early analysis showed participants had a three times higher likelihood of improving their percent predicted forced expiratory volume in 1 second (ppFEV1) when receiving ETD001 compared to placebo.
The results, which prove ETD001 can improve lung function, also show ETD001 was overall well-tolerated in patients.
“We are delighted to report positive results from this Phase II trial of ETD001,” said Dr Renu Gupta, CMO at Enterprise Therapeutics.
“These data demonstrate that this novel, inhaled ENaC blocker is well tolerated in pwCF [people with CF) and has shown improvement in lung function over a 28-day period compared to placebo.
“We are encouraged by the potential of ETD001 to be a novel therapeutic option for improving the lives of all pwCF, particularly those currently without effective therapies, and we are grateful to everyone who took part in this trial.”
